Literature DB >> 11052179

The inhibitory action of butyrate on lipopolysaccharide-induced nitric oxide production in RAW 264.7 murine macrophage cells.

D Chakravortty1, N Koide, Y Kato, T Sugiyama, M M Mu, T Yoshida, T Yokochi.   

Abstract

The effect of butyrate, a natural bacterial product of colonic bacterial flora, on lipopolysaccharide (LPS)-induced nitric oxide (NO) production in RAW 264.7 murine macrophage cells was studied. Butyrate significantly reduced NO production in LPS-stimulated RAW cells. The inhibition was abolished by the removal of butyrate. Butyrate also inhibited the expression of inducible type NO synthase (iNOS) in LPS-stimulated RAW cells. Furthermore, butyrate prevented the activation of nuclear factor (NF)-kappaB through the stabilization of IkappaB-alpha and IkappaB-beta. Butyrate did not affect the phosphorylation of mitogen-activated protein (MAP) kinases by LPS. It was, therefore, suggested that butyrate down-regulated LPS-induced NO production in RAW cells through preventing the expression of iNOS, and that it was due to the inhibitory action of butyrate on the activation of NF-kappaB.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11052179

Source DB:  PubMed          Journal:  J Endotoxin Res        ISSN: 0968-0519


  18 in total

1.  The p50-p50 NF-kappaB complex as a stimulus-specific repressor of gene activation.

Authors:  Xin Tong; Lei Yin; Raymond Washington; Daniel W Rosenberg; Charles Giardina
Journal:  Mol Cell Biochem       Date:  2004-10       Impact factor: 3.396

Review 2.  Immunological mechanisms underpinning faecal microbiota transplantation for the treatment of inflammatory bowel disease.

Authors:  M N Quraishi; W Shaheen; Y H Oo; T H Iqbal
Journal:  Clin Exp Immunol       Date:  2019-11-27       Impact factor: 4.330

3.  Inhibition of histone deacetylases prevents cytokine-induced toxicity in beta cells.

Authors:  L Larsen; M Tonnesen; S G Ronn; J Størling; S Jørgensen; P Mascagni; C A Dinarello; N Billestrup; T Mandrup-Poulsen
Journal:  Diabetologia       Date:  2007-01-31       Impact factor: 10.122

4.  Histone deacetylase inhibitor KBH-A42 inhibits cytokine production in RAW 264.7 macrophage cells and in vivo endotoxemia model.

Authors:  Yongseok Choi; Song-Kyu Park; Hwan Mook Kim; Jong Soon Kang; Yeo Dae Yoon; Sang Bae Han; Jeung Whan Han; Jee Sun Yang; Gyoonhee Han
Journal:  Exp Mol Med       Date:  2008-10-31       Impact factor: 8.718

5.  Histone deacetylase inhibitor, butyrate, attenuates lipopolysaccharide-induced acute lung injury in mice.

Authors:  Yun-Feng Ni; Jian Wang; Xiao-Long Yan; Feng Tian; Jin-Bo Zhao; Yun-Jie Wang; Tao Jiang
Journal:  Respir Res       Date:  2010-03-20

Review 6.  The Role of the Microbial Metabolites Including Tryptophan Catabolites and Short Chain Fatty Acids in the Pathophysiology of Immune-Inflammatory and Neuroimmune Disease.

Authors:  Gerwyn Morris; Michael Berk; Andre Carvalho; Javier R Caso; Yolanda Sanz; Ken Walder; Michael Maes
Journal:  Mol Neurobiol       Date:  2016-06-27       Impact factor: 5.590

Review 7.  Histone deacetylase regulation of immune gene expression in tumor cells.

Authors:  A Nazmul H Khan; Thomas B Tomasi
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

Review 8.  Nitric oxide as a target of complementary and alternative medicines to prevent and treat inflammation and cancer.

Authors:  Lorne J Hofseth
Journal:  Cancer Lett       Date:  2008-04-25       Impact factor: 8.679

9.  Staphylococcus epidermidis in the human skin microbiome mediates fermentation to inhibit the growth of Propionibacterium acnes: implications of probiotics in acne vulgaris.

Authors:  Yanhan Wang; Sherwin Kuo; Muya Shu; Jinghua Yu; Stephen Huang; Ashley Dai; Aimee Two; Richard L Gallo; Chun-Ming Huang
Journal:  Appl Microbiol Biotechnol       Date:  2013-11-22       Impact factor: 4.813

10.  Regulation of microglial inflammatory response by sodium butyrate and short-chain fatty acids.

Authors:  Jari Huuskonen; Tiina Suuronen; Tapio Nuutinen; Sergiy Kyrylenko; Antero Salminen
Journal:  Br J Pharmacol       Date:  2004-01-26       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.